How much revenue does GlaxoSmithKline Pharmaceuticals make?

GlaxoSmithKline Pharmaceuticals reported 38.22 billion INR in revenue for fiscal year 2026, up 2.6% from 37.26 billion INR in fiscal year 2025. In Q1 2027 revenue was 9.38 billion INR.

What companies are similar to GlaxoSmithKline Pharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Biocon Limited (BIOCON.NS), Abbott India Limited (ABBOTINDIA.NS), Ipca Laboratories Limited (IPCALAB.NS), Ajanta Pharma Limited (AJANTPHARM.NS).

GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) Stock

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granul...

At a glance

GlaxoSmithKline Pharmaceuticals reported revenue of 38.22 billion INR for fiscal year 2026, up 2.6% from fiscal year 2025, and net income of 10.36 billion INR. In Q1 2027 (the quarter ended June 30, 2026) revenue was 9.38 billion INR, up 16.6% from a year before.

Figures from company filings; latest fiscal year ended March 31, 2026.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.